|
Nigerian Journal of Physiological Sciences
Physiological Society of Nigeria
ISSN: 0794-859X
Vol. 19, Num. 1-2, 2004, pp. 48-52
|
Nigerian Journal of Physiological Sciences, Vol. 19, No. 1-2, June/Dec,
2004, pp. 48-52
PULMONARY PERFORMANCE IN
ASYMPTOMATIC YOUNG NIGERIAN POPULATION FOLLOWING THE ADMINISTRATION OF ASCORBIC
ACID AND SALBUTAMOL
S. O. ODEH1, I.E. AGABA2, A. M. SABO 1, and R. A. ODANAOGUN 1
1
Department of Human Physiology, 2 Department of Medicine and
Radiology, University
of Jos, Jos, Nigeria, E-mail:
oyioche01@yahoo.com., odehs@unijos.edu.ng.
Received: October 6, 2004
Accepted: November 18, 2004
Code Number: np04009
SUMMARY
The relationship
between vitamin C and pulmonary function has been reported to be a protection
against pulmonary dysfunction. Sympathomimetics like salbutamol are
respiratory smooth muscle relaxants. This study is aimed at investigating the
roles of vitamin C and salbutamol on pulmonary function in a Nigerian
population. Undergraduate medical students who gave their informed consent were
clinically screened and thirty (30) selected. The subjects were grouped, and
given Ascorbic acid and Salbutamol. Spirometry and peak flow measurements were
done on each subject. Ascorbic acid was given orally at a dose of 1.50 mg
/kg body weight; and salbutamol at a dose of 70 mg/kg
body weight, orally. Measurements were taken an hour after each administration
of the drugs.
Results show mean PEFR in male
and female control as 485.76 ±51.40
L/min, and 329.87 ±34.90 L/min
respectively. Ascorbic acid increases PEFR much more than salbutamol VT,
ERV, IC, VC and IRV were increased by ascorbic acid while Salbutamol decreased
ERV, IC, VC and IRV. The study supports the performance enhancing role of
ascorbic acid, more pronounced in the males than females. There do not seem to
be any beneficial roles of salbutamol in asymptomatic individuals.
Key Words: Lung
function, Ascorbic acid, Salbutamol
INTRODUCTION
Lung volume is a determinant of the vascular
resistance in the pulmonary bed. The mechanism of breathing involves interplay
of forces supporting and moving the lungs with the chest wall, in addition to
overcoming resistance. The elasticity of the lungs is conventionally believed
to be dependent on the surfactant (West, 1990, Gala et al, 1998).
Analysis of
static pressure volume data could be useful in the identification of
pulmonary function abnormality, and in the probable categorization of the
dominant mechanism for restrictive ventilatory defects (Aggarwal et al, 2000).
Topulos et al (2001) posited that pressure volume characteristics of the lungs
microcirculation are important determinants of pulmonary perfusion. It is
however, not yet clear, whether muscle function can be used to predict
respiratory changes in exercise limitations (Mayer et al, 2000). Exercise
limitation is usually associated with reversible lung restriction and
inefficient ventilation at rest and during exercise (Aggarwal et al, 2000).
The b-agonists has relaxant effects on
respiratory smooth muscles, acting through the calcium cyclic adenosine
monophosphate (cAMP) mechanism. They also have anti permeability effects
preventing histamine induced microvascular efflux of protein and fluid
(Anderson and Johnson, 1979). The effects of ascorbic acid on pulmonary
function have been investigated (Hu et al, 1998, Ibadin and Osubor, 1999).
Weber et al (1996) reported that ascorbic acid protects against pulmonary
dysfunction. Ascorbic acid is an antioxidant (Grievink et al, 1998).
Sympathomimetics (e.g. Salbutamol) are being used in the treatment of
obstructive pulmonary diseases following the Henry Perrsons discovery of the
b - adrenoceptor selectivity (Lands et
al, 1997).
The support of
baseline absolute lung volumes on clinical decision making is claimed not to
be necessarily great (Walamies, 1998). However, the implication of pulmonary
function defects on several clinical conditions can only but justify the value
of lung volume studies in clinical decision making (Igneito et al 1998; Yap et
al, 2000: Cassino et al, 2001; Fuyita et al, 2001). In our environment,
ascorbic acid and sympathomimetics are frequently used clinically, and even on
self medications. Therefore, the study is carried out to compare the effects
of ascorbic acid and salbutamol on lung function of asymptomatic subjects.
MATERIALS AND METHODSThe study was carried out on volunteer
undergraduate medical students who gave their informed consent. The subjects
were interviewed and physically examined. Those with respiratory and or
cardiovascular disorders were excluded. Thirty (30) subjects made up of
fifteen (15) males and females each were randomized to control, ascorbic acid,
and salbutamol groups.
Each subject
had peak flow measurements and spirometry done. The Spirometer was filled with
water to level mark, and the recorder adjusted to 4.5L mark. The age, weight
and height of the subjects were taken. Each subject was comfortably seated,
and connected to the apparatus. Recordings were taken at a drum speed of 2.5
mm/sec.
Drug Administration:
The ascorbic acid
was given orally at a dose of 1.5 mg/kg body weight, and salbutamol at a dose
of 70 mg/kg body weight, also orally.
Measurements were taken after one hour of the administration of drugs.
Data Analysis:
The data was analyzed using the statistical package
for Social Sciences, version 8.0. The students t-test was employed. The
level of significance was taken to be 95% confidence limit (P<0.05).
RESULTS
Subject Characteristics:
The mean age of the male
subjects was 22.87 years and for the female, 22.01 years. The mean weights
were 63.46 kg and 61.09 kg male and female respectively. The mean heights were
1.71 m for males and 1.68 m for females. These are shown in Table I.
Peak flow measurements:
The peak flow rate in the control groups for males
and females were 485.78 ± 51.45 L/min
and 329.87 ±34.90 L/min respectively.
The PEFR in the male was significantly higher than in the female control group
(P<0.05). The PEFR for the ascorbic
acid groups were 571.00 ±37.16 L/min
and 333.00 ±36.42 L/min for males and
females respectively. The male ascorbic acid group was significantly higher
than the control group (P<0.05) and
the female group (P<0.05). The PEFR
in the salbutamol groups were 513.26 ±31.96 L/min in the male and 389.66 ±16.05 L/min in the female groups respectively. PEFR was raised in the
salbutamol groups, but not significantly higher than the controls (P<0.05). The male salbutamol group
differs significantly from the female group (Table 2).
The results for
the spirometry are shown in Table 3. Tidal Volume (VT ) in the
control groups are 0.60 ±0.11L and
0.55 ±0.11 L in the males and the
females respectively. The expiratory reserve volume (ERV) was significantly
higher (P<0.05) in the male ascorbic
acid group, and lower (P<0.05) in
the male salbutamol group. There are no significant changes in the female
group. The inspiratory capacity (IC) was not significantly different in the
male group on ascorbic acid (P<0.05),
but Salbutamol significantly lowers IC in the females (P<0.05). Vital capacity (VC) is significantly (P<0.05) raised in the male by ascorbic
acid, and in the female by salbutamol. The inspiratory reserve volume (IRV)
did not show any significant difference from the control for any of the test
groups.
Table I: Some Anthropometric
data of subjects used in the study
|
Mean Age (Years)
|
Mean Height (m)
|
Mean weight (kg)
|
Male
|
22.87
|
1.71
|
63.46
|
Female
|
22.01
|
1.68
|
61.09
|
Table 2: Mean Peak Expiratory Flow Rate following
the administration of Ascorbic acid and Salbutamol (L/min)
|
Male
|
Female
|
Control
|
485.76 ±51.45 L/min
|
329.87 ±34.90 L/min
|
Ascorbic acid
|
571.00 ±37.16 L/min
|
333.00 ±36.42 L/min
|
Salbutamol
|
513.26 ±31.96 L/min
|
389.66 ±16.05 L/min
|
Table 3: Mean Lung
Volumes and capacities following the administration of ascorbic acid and
salbutamol (L)
|
Control
|
Ascorbic Acid
|
Salbutamol
|
|
Male
|
Female
|
Male
|
Female
|
Male
|
Female
|
VT
|
0.60 ±0.11
|
0.55 ±0.11
|
0.76 ±0.12
|
0.65 ±0.12
|
0.79 ±0.15
|
0.63 ±0.12
|
ERV
|
1.2 ±0.18
|
0.98 ±0.13
|
1.72 ±0.23
|
1.02 ±0.11
|
0.82 ±0.17
|
0.92 ±0.14
|
IC
|
3.66 ±0.22
|
2.64 ±0.15
|
3.93 ±0.24
|
3.39 ±0.10
|
2.63 ±0.16
|
2.39 ±0.21
|
VC
|
4.66 ±0.15
|
4.18 ±0.18
|
5.59 ±0.33
|
4.91 ±0.05
|
3.56 ±0.02
|
3.45 ±0.30
|
IRV
|
2.82 ±0.17
|
2.58 ±0.12
|
2.97 ±0.12
|
2.73 ±0.13
|
2.13 ±0.10
|
2.01 ±0.25
|
Key
VT - Tidal
Volume
ERV - Expiratory
Reserve Volume
IC - Inspiratory
Capacity
VC - Vital
Capacity
IRV - Inspiratory
Reserve Volume
DISCUSSION
The standard value for peak
expiratory flow rate (PEFR) is between 510 and 560 L/min (Slonim and Hamilton,
1987). In our study, the PEFR value of 485 L/min is lower than this range.
Ascorbic acid (Vitamin C) improved the PEFR to 571 L/min. This study does not
corroborate the study of Ibadin and Osubor (1999) which reported a lack of
effect of vitamin C on pulmonary function. Vitamin C protected against loss of
pulmonary function (Hu et al, 1998) Grievmik et al, (1998) also supported the
beneficial role of vitamin C in respiratory dysfunction.
In the present
study, the male PEFR values are expectedly higher than female values (485 L/min
and 329 L/min respectively). The vitamin C effect shows a significant (P<0.05) increase in PEFR, indicating a
minimal response of smooth muscle to sympathomimetics. Lands et al (1967)
posited that the b- adrenoceptor
agonists actually become important in obstructive pulmonary disorders. The
report of Perrson (1979) that the effect of b-
agonist is more pronounced in healthy lungs compared to diseased lungs, is not
corroborated by the present study.
The tidal
volume in the control group (0.6L and 0.55 L for males and females
respectively) corroborated the standard values of 0.5L to 0.6L. Ascorbic acid
and salbutamol did not significantly increase the VT in both sexes
(P>0.05). Expiratory reserve volume
(ERV) in our study population was lower for all groups than the standard values
of 1.0L to 1.2L. Vitamin C increased ERV in males but not in females, while
Salbutamol decreased ERV in males (P<
0.05) but not in females (P >
0.05). ERV reflects the thoracic and abdominal muscles strength, thoracic
mobility and a balance of elastic forces affecting spontaneous expiration (Gelb
and Zamel, 2001). Our subjects have less reserve expiratory capabilities.
This might be due to the fact that most medical students are not engaged in active
regular bodily exercises.
The
inspiratory reserve volume IRV in our study is significantly lower than the
standard values. Ascorbic acid increases IRV in both sexes while salbutamol
decreases it. IRV describes a balance between lung and chest elasticity,
muscle strength and thorax mobility.
Vital capacity
(VC) describes the physical unit of the rising tidal volume during maximal
ventilatory effort. Our study shows a reduced VC in controls and in the
salbutamol group. Ascorbic acid significantly (P < 0.05) increases VC. VC is usually reduced in severe
respiratory muscle weakness (Syabbalo, 1998).
Discrepancies
in IRV and ERV may be explained by a lack of parenchymal airway narrowing
(Stanescu et al, 200). The IC is more frequently used than IRV. At low
volumes, it is expected that the vasculature would strain and stiffen (Topulos
et al, 2000; Schulz et al, 1999). Our study shows IC rising with ascorbic acid
and falling with salbutamol. The exact mechanism of action is yet to be
elucidated. It however corroborates the hypothesis that ascorbic acid protects
against the loss of pulmonary function. Hu et al, (1998) have indeed reported
an inverse relationship between vitamin C and cough. The relatively lower
value in females in the present study corroborated the report that progesterone
reduces fatigue and lowers exercise tolerance (Van-Haren et al, 1998).
The Salbutamol
response in this study supports earlier works (Pillet et al, 1998) which reported
that b - agonist bronchodilators induce hypoxic
vasoconstriction with no significant influence on ventilation parameters.
Ascorbic acid indeed has
beneficial effect on pulmonary function.
Our study has
the limitation of sample size, being a preliminary study. It is intended that
in subsequent work, the sample size would be increased, and we would attempt to
define the mechanism of ascorbic action effect on ventilatory efforts.
ACKNOWLEDGEMENTS
The authors
gratefully acknowledge the technical assistance offered by the Laboratory Staff
of the Physiology Department, University of Jos.
REFERENCES
-
Aggarwal A.N; Gupta; Behera D. and Jindal S.K. (2000). Analysis of
static pulmonary mechanics helps to identify functional defects in survivors
of acute respiratory distress syndrome. Critical Care Medicine. 28 (10):
-
Andresson R.G.G. and Johansson S.R.M. (1979) B adrenoceptors and the
CAMP System. Acta Pharmalogica of Toxicologica. 449 (1).
-
Becker M.D: Berkmen; Austin J.H; Mun I.K. Ronney B.M.; Rozenhtien A;
Jellen P.A; Yip C.K, Thomashow B; and Ginsburg M.E. (1998). Lung Volume
before and after lung volume reduction surgery: Quantitative C T analysis. American
Journal of Respiration and Critical Care Medicine. 157 (5 part 1):
1593-1599.
-
Cassino C; Berger K.I; Goldring R.M; Norman R.G, Kammerman S; Ciotoli
C; Reibman J. (2000). Duration of Asthma and Physiologic outcomes in elderly
non Smokers. American Journal Respiration and Critical Care Medicine.
162 (4 Part 1): 1423-1428.
-
Corzo-Alvarez G.R. (1998); Lung Volumes in non smoking healthy in
Maracaibo, Venezuela. Investigation Clinic. 39 (1): 3-17.
-
Fujita K; Shannon J.M; Irvin C.G; Fagon K.A; Cool C; Augustin A. and
Mason R. J. (2001) Over expression of tumour necrosis factor alpha produces an
increase in lung volume and Pulmonary hypertension. American Journal of
Physiology, Lung, Cell, and Molecular Physiology 280(1): L 39-49.
-
Galal M.W; Habib R.A; Jaeger D.D. and Lister G. (1998). Effects of
rate amplitude of breathing on respiratory system elastance and resistance
during growth of healthy children. Pediatric Pulmonology. 25(4):
270-277.
-
Gelb A.F. and Zamel N. (2000). Unsuspected pseudo physiologic
emphysema in chronic persistence Asthma. American Journal of Respiration
and Critical Care Medicine. 162(5): 1778-1782.
-
Grievink L; Smith H.A; Ocke M.C Vant Veer P; Kromhout D. (1998). Dietary
intake of antioxidant (pro) vitamins; respiratory symptoms and pulmonary
function: the MORGEN Study. Thorax. 53 (3): 166-171.
-
Grimm D.R; Chandy D; Almenott P.L; Schilero G; and Lesser (2000).
Airway function: the tetraplegia is associated with reduced base line airway
caliber. Chest. 118(5): 1397-1404).
-
Hu G; Zhang X; Chen J; Peto R; Campbell T.C and Cassino P.A (1998). Dietary
Vitamin C intake and Lung Function in rural China. American Journal
of Epidemiology. 148(6): 594-599.
-
Ibadin M.O. and Osubor C.C. (1999). Plasma Ascorbic acid status in
Nigerian Children with bacterial upper respiratory tract infection. Nigerian
Medical Practitioner. 37 (1.2): 18-20.
-
Ingenito E.P; Evans R.B; Loring S.H; Kaczka D.W, Roden house J.D; Body
S.C; Sugarbaker D.J; Mentzer S.J; Decamp M.M and Reilly J.J (1998). Relation
between preoperative inspiratory Lung Resistance and the outcome of Lung
Volume reduction surgery for emphysema.. New England Journal of
Medicine. 338(17): 1181-1185.
-
Lands A.M; Arnold A; Mc- Auliff J.P Luduena F.P and Brown Jr T.G.
(1967). Differentiation of receptor systems activated by Sympathomimetic
amines. Nature. 214: 597-598.
-
Meyer F.J; Zugck C; Hanss M; Ottespoor L; Strasser R.H; Kubler W; and
Borst M.M. (2000). Inefficient ventilation and reduced respiratory muscle
capacity in congestive cardiac failure. Basic Research in Cardiology. 95(4):
333-342.
-
Monso E; Fiz J.M; Izquierdo J; Alonso
J, Coll R; Rosell A. and Morera J. (1998). Quality of life in severe chronic
obstructive pulmonary disease: correlaltion with Lung and
muscle function. Respiratory Medicine. 92(2): 221-227.
-
Persson C.G.A. (1979). B Receptor agonist and permeability in the
Lung. Acta Pharmacological et Toxicologica. 44 (11): 33-35.
-
Pillet O; Manier G. and Castaing Y. (1998) Anticholinergic versus beta
2 agonist on gas exchange in COPD; a comparative study in fifteen patients
Monaldi Archive of Chest Diseases. 53 (1):3-8.
-
Schylz H; Eder G; Heillmann P; Karg E; Meyer T; Schulz A; Ziesenis A;
and Hayder J. (1999) Health effects of Sulphur related environmental
air population iv: respiratory Lung function. Inhalation and Toxicology.
11(5): 423-438.
-
Slonim N.B and Hamilton L.H. (1987). Respiratory Physiology. 5th
ed. The CV Mosby Company, Toronto pp 48-52.
-
Stanescu D; Veriter C; Van de Woesstijine K.P. (2000). Maximal
Inspiratory flow rates in patients with COPD. Chest 118 (4): 976-980.
-
Syabbalo N. (1998). Assessment of Respiratory Muscle Functions and
strength. Postgraduate Medical Journal. 74(870): 208-215.
-
Topulos G.P; Brown R.E and Butler J.P. (2000). Influence of Lung
Volume on Pulmonary micro vascular pressure volume characteristics. Journal
of Applied. Physiology. 89 (4): 1591-1600.
-
Van Haren E.H; Davies I.E; Mol M.J and Kondijs J.W. (1998)..Asthma
en zwangerschap. Ned J Tijdschr Geneeskd. 142 (11): 526-566.
-
Walamies M.A. (1998). Diagnostic role of residual volume in paediatric
patients with chronic symptoms of the lower airways. Clinical Physiology.
18(1): 49-54.
-
Weber C; Erl W; Weber K; and Weber P.C. (1996). Increase adhesiveness
of isolated monocytes to endothelium presented by vitamin C intake in smokers. Circulation 93
(8): 1488 1492.
-
West J.B. (1990). Ed: Best and Taylors Physiological Basis of Medical
Practice. 11th ed. Williams and Williams. London. pp 54-550.
-
Yap J.C; Moore D.M Cleland J.G and Pride N.B (2000). Effect of supine
posture on Respiratory Mechanics in Chronic left ventricular failure. American
Journal Respiration and Critical Care Medicine. 162(4 part 1): 1285-1291.
-
Yernault J.C; Pride N; and Laszlo G. (2000). How the measurement of
residual volume developed after Davey (1800). European Respiratory Journal.
16 (3): 561-564.
© Physiological Society of Nigeria 2004
|